Use of computational systems biology techniques might enable integration of complex information derived from genomics, epigenetics, immunology, proteomics, etc. to design effective strategies to overcome acquired ICI resistance and expand the reach of anti-PD-1/PD-L1 agents to a greater number of NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.